<DOC>
	<DOCNO>NCT00005998</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy peripheral stem cell transplantation use specially treat stem cell may allow doctor give high dos chemotherapy drug radiation therapy kill cancer cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation use specially treat stem cell treat patient non-Hodgkin 's lymphoma Hodgkin 's disease .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation With Specially Treated Stem Cells Treating Patients With Non-Hodgkin 's Lymphoma Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether prim hematopoietic cytokine chemotherapy increase yield hematopoietic progenitor peripheral blood stem cell ( PBSC ) patient non-Hodgkin 's lymphoma Hodgkin 's disease undergo autologous PBSC transplantation . - Determine whether vitro study predict transduction efficiency early late engraft hematopoietic stem cell patient population undergo treatment . - Determine whether vitro transduction graft product stable long term transduction marrow cell patient autologous transplantation . OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) twice daily day 1-7 . Peripheral blood stem cell ( PBSC ) collect day 5-7 . Patients receive cyclophosphamide IV 2 hour , mitoxantrone IV , cytarabine IV every 12 hour 2 dos day 10 , dexamethasone every 12 hour 4 dos day 10 11 . Patients receive G-CSF SC next 10-20 day . Additional PBSC collect day 25-28 29 . Beginning 7 day PBSC transplantation , patient receive cyclophosphamide IV 2 hour day -7 -6 total body irradiation ( TBI ) twice daily day -4 -1 . Patients unable tolerate TBI receive cyclophosphamide IV 2 hour day -6 -3 , carmustine IV 1 hour day -6 , etoposide IV 1 hour every 12 hour day -6 -4 . Retrovirally transduced PBSC reinfused day 0 follow another course G-CSF SC hematopoietic recovery . Patients follow 1 , 3 , 6 , 9 , 12 , 18 , 24 month annually thereafter . PROJECTED ACCRUAL : A total 15-20 patient accrue study within 12-15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Intermediate high grade nonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease ( HD ) Chemotherapy sensitive , initial partial remission OR Relapse initial complete partial remission Low grade NHL eligible provide progression follow initial partial complete remission Ineligible ongoing allogeneic marrow donor transplant protocol elect participate protocols No chemotherapy resistant NHL HD NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Karnofsky 90100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : AST le 2.5 time upper limit normal ( ULN ) Bilirubin le 2.5 time ULN Renal : Creatinine le 2.0 mg/dL Cardiovascular : Resting LVEF least 40 % No unstable ischemic heart disease Pulmonary : Spirometry DLCO great 50 % predict Other : No active uncontrolled infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>